Search results
Results From The WOW.Com Content Network
Many bioethical concerns have been raised about the prospect of using CRISPR for germline editing, especially in human embryos. [12] In 2023, the first drug making use of CRISPR gene editing, Casgevy, was approved for use in the United Kingdom to cure sickle-cell disease and beta thalassemia.